Abstracts tagged "Morbidity and mortality and systemic sclerosis"

Abstract Number: 2696 • 2018 ACR/ARHP Annual Meeting
Increased Mortality in Black and Asian Patients with Systemic Sclerosis in Northern California
Melody Chung¹, Makdine Dontsi², Debbie Postlethwaite², Sumana Kesh³, Lisa Zaba⁴ and Lorinda Chung^5,6, ¹Internal Medicine Residency, Kaiser Permanente Santa Clara, Santa Clara, CA, ²Division of Research, Kaiser Permanente Northern California, Oakland, CA, ³Department of Internal Medicine, Kaiser Permanente Santa Clara, Santa Clara, CA, ⁴Department of Dermatology, Kaiser Permanente Santa Clara, Santa Clara, CA, ⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁶VA Palo Alto Health Care System, Palo Alto, CA
Background/Purpose: Studies indicate that black patients with systemic sclerosis (SSc) demonstrate a distinct phenotypic profile, with more severe disease, heightened mortality, and poorer prognosis compared…
Abstract Number: 944 • 2017 ACR/ARHP Annual Meeting
Long-Term Survival and Follow-up of Anti-Th/to Antibody Positive Systemic Sclerosis Patients
Devon Charlton¹, Maureen Laffoon², Thomas A. Medsger Jr.³ and Robyn T. Domsic⁴, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Anti-Th/To antibody is an autoantibody associated with systemic sclerosis (SSc), occurring in 5-10% of patients. To date, only relatively small case series have described…
Abstract Number: 1699 • 2017 ACR/ARHP Annual Meeting
A 10-Year National Trend in Acute Coronary Syndrome Among Hospitalized Patients with Systemic Sclerosis
Yiming Luo¹, Jiehui Xu², Yumeng Wen¹, Changchuan Jiang¹, Shuyang Fang¹, Mustafa Kagalwalla¹, Xin Wei¹ and Bing Yue¹, ¹Department of Medicine, Mount Sinai St Luke's and Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, NY
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disorder characterized by microvascular changes, excessive fibrous tissue deposition and systemic inflammation. Previous studies showed that systemic…
Abstract Number: 2689 • 2017 ACR/ARHP Annual Meeting
Troponinemia Independently Associates with Mortality in Systemic Sclerosis
Julie J. Paik¹, Debbie Choi¹, Fredrick M. Wigley², Laura K. Hummers³ and Ami A. Shah¹, ¹Johns Hopkins University, Baltimore, MD, ²Rheum Div/Mason F Lord, Johns Hopkins University, Baltimore, MD, ³Medical and Rheumatology, Johns Hopkins University, Baltimore, MD
Title: Troponinemia independently associates with mortality in systemic sclerosis Background/Purpose: Cardiac involvement is common in systemic sclerosis (SSc) and in the early asymptomatic stages, elevated…
Abstract Number: 827 • 2016 ACR/ARHP Annual Meeting
Severe Gastrointestinal Disease in Early Systemic Sclerosis Is Associated with an Increased Risk of Mortality
Nicolas Richard¹, Marie Hudson², Mianbo Wang³, Murray Baron⁴, Genevieve Gyger¹ and Canadian Scleroderma Research Group, ¹McGill University, Jewish General Hospital, Montreal, QC, Canada, ²Medicine/Rheumatology, Jewish General Hospital, Lady Davis Research Institute, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Studies of severe gastrointestinal (GI) disease in systemic sclerosis (SSc) are limited by small, selected samples composed largely of subjects with prevalent disease. We…
Abstract Number: 1238 • 2016 ACR/ARHP Annual Meeting
Assessment of Mortality and Healthcare Costs Associated with Systemic Sclerosis with and without Lung Involvement
Karina Raimundo¹, Amanda Farr², Ashley Cole³ and Aryeh Fischer⁴, ¹Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ²Truven Health Analytics, Cambridge, MA, ³Truven Health Analytics, Bethesda, MD, ⁴Medicine / Center for Lungs and Breathing, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Patients with systemic sclerosis (SSc) are at high risk of developing interstitial lung disease (ILD) and/or pulmonary hypertension (PH). These two lung manifestations are…
Abstract Number: 2906 • 2016 ACR/ARHP Annual Meeting
The Survival and Prognostic Factors of Patients with Systemic Sclerosis Turkish Experience
Orhan Zengin¹, Mehmet Ali Balci², Omer Nuri Pamuk², Bunyamin Kisacik¹, Salim Donmez², Mustafa Erkut Onder¹, Savas Aksoy¹ and Ahmet Mesut Onat¹, ¹Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ²Rheumatology, Trakya University Medical Faculty, Edirne, Turkey
Background/Purpose: Systemic sclerosis (SSc) is a low-prevalence disease, characterized by fibrosis and vascular changes. It is the auto-immune rheumatic disease with the highest disease-related mortality…
Abstract Number: 828 • 2015 ACR/ARHP Annual Meeting
Development of a Disease Damage Index in Systemic Sclerosis Using Consensus and Data Driven Methods
Nava Ferdowsi¹, Molla Huq¹, Jodie Burchell², Sam Mancuso², Tien Tay^1,3, Wendy Stevens⁴, Candice Rabusa⁴, Marie Hudson⁵, Vijaya Sundararajan², David Prior⁶, Susanna Proudman⁷, Murray Baron⁸ and Mandana Nikpour^9,10, ¹Rheumatology, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ²Medicine, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ³41 Victoria Parade, Fitzroy, St Vincent's Hospital, Melbourne, Australia, ⁴Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁵Medicine, McGill University, Montreal, QC, Canada, ⁶Cardiology, St Vincent's Hospital, Melbourne, Australia, ⁷Rheumatology Unit, Royal Adelaide Hospital North Terrace, Adelaide, Australia, ⁸Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ⁹St Vincent's Hospital, Melbourne, Australia, ¹⁰Medicine, The University of Melbourne at St. Vincent’s Hospital, Melbourne, Australia
Background/Purpose: As there is currently no existing index for quantifying organ damage in systemic sclerosis (SSc), we sought to develop a disease damage index in…
Abstract Number: 843 • 2015 ACR/ARHP Annual Meeting
Natriuretic Peptide Predicts Mortality in Systemic Sclerosis
Christophe Meune¹, Andras Komocsi², Serena Vettori³, Eric Hachulla⁴, Jerome Avouac⁵, Nicolas Hunzelmann⁶, Jorg HW. Distler⁷ and Yannick Allanore⁸, ¹Cardiology department, Université Paris XIII, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Bobigny, France, ²Heart Institute, University of PECS, Pecs, Hungary, ³Department of Clinical and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁴CHU Lille, Lille, France, ⁵Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ⁶Department of Dermatology, University of Cologne, Cologne, Germany, ⁷Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Paris Descartes University, Rheumatology A department, Cochin Hospital, And Eular Scleroderma Trials And Research (EUSTAR) Board, Paris, France
Background/Purpose: Heart involvement both of primary origin or secondary to lung disease is a key contributor to morbidity and mortality in systemic sclerosis (SSc). While…
Abstract Number: 846 • 2015 ACR/ARHP Annual Meeting
Nationwide Trends in in-Hospital Mortality and Hospitalization Associated with Systemic Sclerosis (SSc)
Sara R. Schoenfeld¹, Na Lu¹, Flavia V. Castelino², Marcy B. Bolster² and Hyon K. Choi¹, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with systemic sclerosis (SSc) experience high rates of morbidity and mortality, but few studies have evaluated health care utilization such as hospitalization rates…
Abstract Number: 1886 • 2015 ACR/ARHP Annual Meeting
Myocardial Fibrosis Detected By Magnetic Resonance Imaging Is a Predictor of Heart Failure in Systemic Sclerosis (SSc) Patients
Tatiana Sofia Rodriguez-Reyna¹, Martha Morelos-Guzmán², Pamela Mercado Velazquez³, Pablo Henrandez-Reyes⁴, Karla Montero-Duarte⁵, Cynthia Martinez-Reyes⁶, Carlos Reyes-Utrera⁶ and Carlos Nunez Alvarez³, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Radiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico, ⁴Department of Cardiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁵Department of Imaging and Radiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: In previous studies we showed that prevalence of myocardial fibrosis in SSc patients is 45% and is associated to diffuse disease (dcSSc) and lower…
Abstract Number: 723 • 2014 ACR/ARHP Annual Meeting
Early Mortality in Australian, Canadian and Spanish Scleroderma Patients: Rationale for Establishing a Multi-National Inception Cohort of Patients with Systemic Sclerosis
YanJie Hao¹, Marie Hudson^2,3, Patricia Carreira⁴, Wendy Stevens^1,5, Candice Rabusa⁶, Solene Tatibouet^7,8, Loreto Carmona⁹, Beatriz E Joven¹⁰, Susanna Proudman^11,12, Murray Baron^7,8 and Mandana Nikpour^1,13, ¹Rheumatology, St. Vincent’s Hospital Melbourne, Melbourne, Australia, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Division of Rheumatology, McGill University, Montreal, QC, Canada, ⁴Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵The University of Melbourne Department of Medicine at St. Vincent’s Hospital Melbourne, Melbourne, Australia, ⁶Rheumatology, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ⁷Rheumatology, Jewish General Hospital, Montreal, QC, Canada, ⁸Rheumatology, Lady David Research Institute, Montreal, QC, Canada, ⁹Instituto de Salud Musculoesqueletica, Madrid, Spain, ¹⁰Rheumatology, Hospital Universitario, Madrid, Spain, ¹¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ¹²Discipline of Medicine, University of Adelaide, Adelaide, Australia, ¹³Medicine, The University of Melbourne at St. Vincent’s Hospital, Melbourne, Australia
Background/Purpose Studies of ‘prevalent' cohorts wherein most patients have longstanding disease at recruitment may underestimate mortality in systemic sclerosis (SSc) due to survivor bias. The…
Abstract Number: 2698 • 2014 ACR/ARHP Annual Meeting
Survival in Systemic Sclerosis-Pulmonary Arterial Hypertension By Serum Autoantibody Status
Monique Hinchcliff^1,2, Saira Khanna³, Jungwha Lee^4,5, Orit Almagor⁶, Rowland W. Chang^2,7, Virginia D. Steen⁸ and Lorinda Chung⁹, ¹Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Preventive Medicine, Northwestern University Medical School, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁹Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Previous studies have shown that anticentromere (AC) and isolated nucleolar (NUC) antibodies are the most common autoantibodies in patients with systemic sclerosis (SSc) and…
Abstract Number: 732 • 2014 ACR/ARHP Annual Meeting
Predictors of Inpatient Mortality in Patients with Systemic Sclerosis: A Case Control Study
Shiv Tej Sehra¹, Chris T. Derk¹, Andrew Kelly² and Joshua Baker³, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Medicine, Pennsylvania Hospital, Philadelphia, PA, ³Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA
Background/Purpose There are few published studies on predictors of inpatient mortality in patients with systemic sclerosis (SSc). Knowledge of these predictors is important for early…
Abstract Number: 2178 • 2013 ACR/ARHP Annual Meeting
Juvenile Onset Systemic Sclerosis: Clinical and Serological Features, and Mortality In Comparison With Adult Onset Disease
Juan G. Ovalles-Bonilla¹, Francisco Javier López-Longo², Indalecio Monteagudo¹, Esperanza Naredo¹, Carlos Gonzalez Fernandez¹, María Montoro Alvarez¹, Lina Martínez-Estupiñán¹, Juan C. Nieto³, Julia Martínez-Barrio¹, Michelle Hinojosa¹, Natalia Bello¹, Belen Serrano¹, Carmen Mata¹ and Luis Carreño¹, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Department of Rheumatology, Madrid, Spain, ³Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Currently data regarding long-term outcome of juvenile systemic sclerosis (jSSc) is scarce. To describe the differences between patients with jSSc versus adult onset evaluated at a single medical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].